Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 8/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.41 |
| ▸ | CDK9 | P50750 | 2/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19785342 | 0.94 | PTPN11 (0.41) | PTPN11CCNT1CDK9IRAK4KCNH2 | |
| SCHEMBL25514397 | 0.91 | PTPN11 (0.44) | PTPN11CCNT1KCNH2 | |
| SCHEMBL25514404 | 0.90 | PTPN11 (0.43) | PTPN11CCNT1KCNH2 | |
| SCHEMBL25514421 | 0.89 | CCNT1 (0.45) | PTPN11CCNT1CDK9IRAK4KCNH2 | |
| SCHEMBL30137467 | 0.88 | PTPN11 (0.53) | PTPN11CCNT1IRAK4KCNH2 | |
| SCHEMBL30511932 | 0.85 | PTPN11 (0.42) | PTPN11KCNH2 | |
| SCHEMBL19785568 | 0.85 | PTPN11 (0.42) | PTPN11KCNH2 | |
| SCHEMBL19785442 | 0.85 | IRAK4 (0.39) | PTPN11CCNT1CDK9IRAK4KCNH2 | |
| SCHEMBL19785441 | 0.85 | IRAK4 (0.39) | PTPN11CCNT1CDK9IRAK4KCNH2 | |
| SCHEMBL30295723 | 0.85 | PTPN11 (0.43) | PTPN11CCNT1IRAK4KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3484856-B1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | REVOLUTION MEDICINES INC (US) | 2023-11-15 | — | — | EP | disclosed |
| CN-116478131-A | 2, 5-disubstituted and 2,5, 6-trisubstituted 3-methylpyrazines as allosteric SHP2 inhibitors | 锐新医药公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-116478132-A | 2, 5-disubstituted and 2,5, 6-trisubstituted 3-methylpyrazines as allosteric SHP2 inhibitors | 锐新医药公司 | 2023-07-25 | — | — | CN | disclosed |
| US-11661401-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661401-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2023-05-30 | — | — | US | disclosed |
| CN-109983001-B | 2, 5-disubstituted 3-methylpyrazines and 2,5, 6-trisubstituted 3-methylpyrazines as allosteric SHP2 inhibitors | 锐新医药公司 | 2023-04-04 | — | — | CN | disclosed |
| US-20220031695-A1 | SHP2 INHIBITOR COMPOSITIONS FOR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-02-03 | — | — | US | disclosed |
| US-20210154190-A1 | SHP2 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | Revolution Medicines, Inc. | 2021-05-27 | — | — | US | disclosed |
| US-20210101870-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-04-08 | — | — | US | disclosed |
| US-20200368238-A1 | SHP2 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2020-11-26 | — | — | US | disclosed |
| US-20190210977-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2019-07-11 | — | — | US | disclosed |
| WO-2018013597-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154190-A1 | SHP2 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | PTPN1, PTPN18, PTPN7 | PTPN11 15/4885CCNT1 4520/4885CDK9 1020/4885 |
| US-11661401-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN22, PTPN2 | PTPN11 8/4885CCNT1 4574/4885CDK9 1689/4885 |
| US-20190210977-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | PTPN5, PTPN2, PTPN22 | PTPN11 12/4885CCNT1 4764/4885CDK9 2034/4885 |
| US-20210101870-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | PTPN5, PTPN22, PTPN2 | PTPN11 8/4885CCNT1 4574/4885CDK9 1689/4885 |
| US-20220031695-A1 | SHP2 INHIBITOR COMPOSITIONS FOR USE IN TREATING CANCER | PTPN18, PTPN7, PTPN1 | PTPN11 14/4885CCNT1 4499/4885CDK9 1212/4885 |
| US-20200368238-A1 | SHP2 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | DUSP3, PTPRCAP, PTPN1 | PTPN11 32/4885CCNT1 3177/4885CDK9 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.